Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -35.50%158.78M | -50.99%23.79M | -49.10%34.38M | -38.56%38.11M | -8.14%62.5M | -32.62%246.16M | -40.56%48.54M | -22.90%67.54M | -32.97%62.04M | -34.26%68.05M |
Cost of revenue | 34.4M | 1.92M | ||||||||
Gross profit | 124.38M | 21.87M | ||||||||
Operating expense | 55.10%931.38M | 0.12%211.99M | 66.96%216.29M | 132.73%292.5M | 57.70%210.6M | -15.57%600.51M | 10.01%211.74M | -26.09%129.55M | -25.65%125.68M | -23.44%133.54M |
Staff costs | 44.19%257.21M | ---- | ---- | ---- | ---- | -20.36%178.38M | ---- | ---- | ---- | ---- |
Selling and administrative expenses | -27.43%162.54M | ---- | ---- | ---- | ---- | 7.50%223.97M | ---- | ---- | ---- | ---- |
-Selling and marketing expense | ---- | ---- | ---- | ---- | ---- | -33.12%66.27M | ---- | ---- | ---- | ---- |
-General and administrative expense | 3.07%162.54M | ---- | ---- | ---- | ---- | 44.36%157.7M | ---- | ---- | ---- | ---- |
Depreciation and amortization | ---- | ---- | ---- | ---- | ---- | -97.20%3.8M | ---- | ---- | ---- | ---- |
-Depreciation | ---- | ---- | ---- | ---- | ---- | -97.20%3.8M | ---- | ---- | ---- | ---- |
Other operating expenses | 163.24%511.63M | ---- | ---- | ---- | ---- | 35.52%194.36M | ---- | ---- | ---- | ---- |
Operating profit | -127.75%-807M | -16.50%-190.13M | -245.78%-214.4M | -299.71%-254.39M | -126.10%-148.09M | -2.45%-354.34M | -47.28%-163.2M | 29.28%-62M | 16.78%-63.64M | 7.65%-65.5M |
Net non-operating interest income (expenses) | -47.59M | -54.61M | 7,323.26%3.19M | 2.72M | 2,676.74%1.11M | 0 | 0 | 43K | 0 | -104.31%-43K |
Non-operating interest income | --12.78M | --5.7M | --3.22M | --2.74M | --1.14M | --0 | --0 | --0 | --0 | --0 |
Non-operating interest expense | --103K | --32K | --23K | --21K | -37.21%27K | ---- | ---- | ---- | --0 | --43K |
Total other finance cost | --60.27M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Net investment income | -608.54%-417K | 358.00%229K | 774.63%586K | 53.02%456K | 414.00%257K | 70.83%82K | -43.82%50K | -39.64%67K | ||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 52.06%-34.89M | -32.04M | 0 | -45K | -2.81M | -72.78M | 0 | 0 | ||
Less:Other special charges | -46.21%34.89M | --32.04M | --0 | --45K | --2.81M | --64.87M | ---- | ---- | ---- | ---- |
Less:Write off | ---- | ---- | ---- | ---- | ---- | --7.91M | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | 46.34%-4.43M | 720.85%53.54M | 2,721.92%2.06M | -48,589.52%-60.13M | -44.44%100K | -1,562.70%-8.25M | -2,128.42%-8.62M | 108.53%73K | 217.95%124K | -74.58%180K |
Income before tax | -105.54%-893.91M | 8.48%-223.63M | -239.07%-209.56M | -390.97%-311.62M | -128.37%-149.11M | -26.28%-434.92M | -119.84%-244.35M | 30.15%-61.81M | 16.11%-63.47M | 5.52%-65.29M |
Income tax | 11.91%1.06M | 47.68%350K | 0.00%237K | 0.00%238K | 0.00%237K | -0.11%949K | -0.42%237K | 0.00%237K | 0.00%238K | 0.00%237K |
Net income | -105.33%-894.97M | 8.43%-223.98M | -238.15%-209.8M | -389.51%-311.85M | -127.90%-149.35M | -26.21%-435.87M | -119.59%-244.59M | 30.07%-62.04M | 16.06%-63.71M | 5.50%-65.53M |
Net income continuous operations | -105.33%-894.97M | 8.43%-223.98M | -238.16%-209.8M | -389.51%-311.85M | -127.90%-149.34M | -26.21%-435.87M | -119.59%-244.59M | 30.07%-62.04M | 16.06%-63.71M | 5.50%-65.53M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -105.33%-894.97M | 8.43%-223.98M | -238.15%-209.8M | -389.51%-311.85M | -127.90%-149.35M | -26.21%-435.87M | -119.59%-244.59M | 30.07%-62.04M | 16.06%-63.71M | 5.50%-65.53M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -105.33%-894.97M | 8.43%-223.98M | -238.15%-209.8M | -389.51%-311.85M | -127.90%-149.35M | -26.21%-435.87M | -119.59%-244.59M | 30.07%-62.04M | 16.06%-63.71M | 5.50%-65.53M |
Gross dividend payment | ||||||||||
Basic earnings per share | -61.43%-50.06 | 32.44%-11.64 | -193.51%-13.12 | -255.35%-16.3104 | -110.59%-9.94 | -24.64%-31.01 | -114.84%-17.23 | 30.16%-4.47 | 15.93%-4.59 | 5.60%-4.72 |
Diluted earnings per share | -61.43%-50.06 | 32.01%-11.7144 | -193.51%-13.12 | -255.35%-16.3104 | -110.59%-9.94 | -24.64%-31.01 | -114.70%-17.23 | 30.16%-4.47 | 16.06%-4.59 | 5.60%-4.72 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |